logo
Kepler Capital Sticks to Their Buy Rating for EDP Renovaveis (0ML1)

Kepler Capital Sticks to Their Buy Rating for EDP Renovaveis (0ML1)

In a report released on May 8, Jose Porta from Kepler Capital maintained a Buy rating on EDP Renovaveis (0ML1 – Research Report), with a price target of €14.00. The company's shares closed last Thursday at €8.10.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Porta is ranked #1103 out of 9472 analysts.
Currently, the analyst consensus on EDP Renovaveis is a Moderate Buy with an average price target of €10.63.
Based on EDP Renovaveis' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of €508.44 million and a net profit of €142.06 million. In comparison, last year the company earned a revenue of €520.75 million and had a net profit of €14.83 million
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Boss Energy (BQSSF) Gets a Hold from Macquarie
Boss Energy (BQSSF) Gets a Hold from Macquarie

Business Insider

time14 minutes ago

  • Business Insider

Boss Energy (BQSSF) Gets a Hold from Macquarie

Macquarie analyst maintained a Hold rating on Boss Energy today and set a price target of A$4.45. The company's shares closed last Friday at $2.39. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Macquarie, Boss Energy also received a Hold from RBC Capital's Alistair Rankin in a report issued on July 17. However, today, Morgan Stanley downgraded Boss Energy (Other OTC: BQSSF) to a Sell. The company has a one-year high of $3.11 and a one-year low of $1.26. Currently, Boss Energy has an average volume of 23.73K.

Kepler Capital Maintained a Buy Rating on Genfit (GNFT)
Kepler Capital Maintained a Buy Rating on Genfit (GNFT)

Yahoo

time19 minutes ago

  • Yahoo

Kepler Capital Maintained a Buy Rating on Genfit (GNFT)

Genfit S.A. (NASDAQ:GNFT) is one of the . On July 8, Justine Telliez from Kepler Capital maintained a Buy rating on Genfit S.A. (NASDAQ:GNFT) with a price target of €8.40. The rating comes after the company released its mid-year update on its liquidity contract with Credit Industriel et Commercial. The company noted that as of June 30, 2025, there were 201,000 shares in the liquidity account along with €398,484.67 in cash in liquidity. Moreover, the company also released details about its trading activity, which shows 1,412,901 shares were bought, 1,419,301 shares were sold, with the number of buy and sell trades standing at 2,673 and 1,894, respectively. A biotechnologist in a laboratory wearing a lab coat, preparing samples for a clinical trial. Genfit S.A. (NASDAQ:GNFT) is a French biopharmaceutical company that develops treatments and diagnostic tools for rare and serious liver diseases. While we acknowledge the potential of GNFT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Kepler Capital Remains Bullish on Novo Nordisk A/S (NVO)
Kepler Capital Remains Bullish on Novo Nordisk A/S (NVO)

Yahoo

time20 minutes ago

  • Yahoo

Kepler Capital Remains Bullish on Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NYSE:NVO) is one of the top low volatility healthcare stocks to buy now. In a report released on July 17, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk A/S (NYSE:NVO) with a price target of DKK630.00. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. Novo Nordisk A/S (NYSE:NVO) reported a 22% growth in operating profit in Danish kroner and 20% at constant exchange rates (CER) to DKK 38.8 billion in the first three months of 2025. Sales in US Operations rose by 20% in Danish kroner and 17% at CER, while sales in International Operations grew by 18% in Danish kroner and 19% at CER in the same period. Novo Nordisk A/S (NYSE:NVO) also experienced a 21% growth in Danish kroner in sales within Diabetes and Obesity care, primarily attributed to the Obesity care growth of 67% in Danish kroner to DKK 18.4 billion and GLP-1 diabetes sales growth of 13% in Danish kroner. Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store